305 related articles for article (PubMed ID: 37265798)
21. Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer.
Mishra A; Wang J; Shiozawa Y; McGee S; Kim J; Jung Y; Joseph J; Berry JE; Havens A; Pienta KJ; Taichman RS
Mol Cancer Res; 2012 Jun; 10(6):703-12. PubMed ID: 22516347
[TBL] [Abstract][Full Text] [Related]
22. Growth Arrest-Specific 6 (Gas6) and TAM Receptors in Mouse Platelets.
Uras F; Küçük B; Bingöl Özakpınar Ö; Demir AM
Turk J Haematol; 2015 Mar; 32(1):58-63. PubMed ID: 25805676
[TBL] [Abstract][Full Text] [Related]
23. Gas6 derived from cancer-associated fibroblasts promotes migration of Axl-expressing lung cancer cells during chemotherapy.
Kanzaki R; Naito H; Kise K; Takara K; Eino D; Minami M; Shintani Y; Funaki S; Kawamura T; Kimura T; Okumura M; Takakura N
Sci Rep; 2017 Sep; 7(1):10613. PubMed ID: 28878389
[TBL] [Abstract][Full Text] [Related]
24. Targeting the TAM Receptors in Leukemia.
Huey MG; Minson KA; Earp HS; DeRyckere D; Graham DK
Cancers (Basel); 2016 Nov; 8(11):. PubMed ID: 27834816
[TBL] [Abstract][Full Text] [Related]
25. Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment.
Myers KV; Amend SR; Pienta KJ
Mol Cancer; 2019 May; 18(1):94. PubMed ID: 31088471
[TBL] [Abstract][Full Text] [Related]
26. AXL receptor tyrosine kinase as a therapeutic target in NSCLC.
Okimoto RA; Bivona TG
Lung Cancer (Auckl); 2015; 6():27-34. PubMed ID: 28210148
[TBL] [Abstract][Full Text] [Related]
27. Gas6-Axl signaling in presence of Sunitinib is enhanced, diversified and sustained in renal tumor cells, resulting in tumor-progressive advantages.
Gustafsson A; Fritz HKM; Dahlbäck B
Exp Cell Res; 2017 Jun; 355(1):47-56. PubMed ID: 28327411
[TBL] [Abstract][Full Text] [Related]
28. Neuroprotective Effects of Omentin-1 Against Cerebral Hypoxia/Reoxygenation Injury via Activating GAS6/Axl Signaling Pathway in Neuroblastoma Cells.
Niu X; Cheng Y; Zhang M; Du L; Wu X; Lu C; Li X; Liu S; Zhao A; Zhang S; Wu Z; Ding B; Shi W; Wang C; Yang Y; Tian Y
Front Cell Dev Biol; 2021; 9():784035. PubMed ID: 35141232
[TBL] [Abstract][Full Text] [Related]
29. The prognostic role of Gas6/Axl axis in solid malignancies: a meta-analysis and literature review.
Zhang S; Xu XS; Yang JX; Guo JH; Chao TF; Tong Y
Onco Targets Ther; 2018; 11():509-519. PubMed ID: 29416351
[TBL] [Abstract][Full Text] [Related]
30. Requirement of Gamma-Carboxyglutamic Acid Modification and Phosphatidylserine Binding for the Activation of Tyro3, Axl, and Mertk Receptors by Growth Arrest-Specific 6.
Geng K; Kumar S; Kimani SG; Kholodovych V; Kasikara C; Mizuno K; Sandiford O; Rameshwar P; Kotenko SV; Birge RB
Front Immunol; 2017; 8():1521. PubMed ID: 29176978
[TBL] [Abstract][Full Text] [Related]
31. Gas6/Axl Axis Activation Dampens the Inflammatory Response in Osteoarthritic Fibroblast-like Synoviocytes and Synovial Explants.
Vago JP; Valdrighi N; Blaney-Davidson EN; Hornikx DLAH; Neefjes M; Barba-Sarasua ME; Thielen NGM; van den Bosch MHJ; van der Kraan PM; Koenders MI; Amaral FA; van de Loo FAJ
Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242486
[TBL] [Abstract][Full Text] [Related]
32. Targeting of TAM Receptors Ameliorates Fibrotic Mechanisms in Idiopathic Pulmonary Fibrosis.
Espindola MS; Habiel DM; Narayanan R; Jones I; Coelho AL; Murray LA; Jiang D; Noble PW; Hogaboam CM
Am J Respir Crit Care Med; 2018 Jun; 197(11):1443-1456. PubMed ID: 29634284
[TBL] [Abstract][Full Text] [Related]
33. Ligand Activation of TAM Family Receptors-Implications for Tumor Biology and Therapeutic Response.
Davra V; Kimani SG; Calianese D; Birge RB
Cancers (Basel); 2016 Nov; 8(12):. PubMed ID: 27916840
[TBL] [Abstract][Full Text] [Related]
34. Gas6/Axl signaling pathway promotes proliferation, migration and invasion and inhibits apoptosis in A549 cells.
Wang D; Bi L; Ran J; Zhang L; Xiao N; Li X
Exp Ther Med; 2021 Nov; 22(5):1321. PubMed ID: 34630675
[TBL] [Abstract][Full Text] [Related]
35. Antibody-mediated neutralization of autocrine Gas6 inhibits the growth of pancreatic ductal adenocarcinoma tumors in vivo.
Moody G; Belmontes B; Masterman S; Wang W; King C; Murawsky C; Tsuruda T; Liu S; Radinsky R; Beltran PJ
Int J Cancer; 2016 Sep; 139(6):1340-9. PubMed ID: 27170265
[TBL] [Abstract][Full Text] [Related]
36. Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects.
Peters S; Paz-Ares L; Herbst RS; Reck M
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35858709
[TBL] [Abstract][Full Text] [Related]
37. Engineered AXL
Duan Y; Hu B; Qiao C; Luo L; Li X; Wang J; Liu H; Zhou T; Shen B; Lv M; Feng J
Oncol Lett; 2019 Jun; 17(6):5784-5792. PubMed ID: 31186805
[TBL] [Abstract][Full Text] [Related]
38. Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR-mutated non-small cell lung cancer.
Nonagase Y; Takeda M; Azuma K; Hayashi H; Haratani K; Tanaka K; Yonesaka K; Ishii H; Hoshino T; Nakagawa K
Thorac Cancer; 2019 Oct; 10(10):1928-1935. PubMed ID: 31419057
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies.
Kariolis MS; Miao YR; Diep A; Nash SE; Olcina MM; Jiang D; Jones DS; Kapur S; Mathews II; Koong AC; Rankin EB; Cochran JR; Giaccia AJ
J Clin Invest; 2017 Jan; 127(1):183-198. PubMed ID: 27893463
[TBL] [Abstract][Full Text] [Related]
40. Inhibiting the GAS6/AXL axis suppresses tumor progression by blocking the interaction between cancer-associated fibroblasts and cancer cells in gastric carcinoma.
Bae CA; Ham IH; Oh HJ; Lee D; Woo J; Son SY; Yoon JH; Lorens JB; Brekken RA; Kim TM; Han SU; Park WS; Hur H
Gastric Cancer; 2020 Sep; 23(5):824-836. PubMed ID: 32239298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
